Consensus on molecular imaging and theranostics in prostate cancer

Stefano Fanti1, Silvia Minozzi2, Gerald Antoch3

  • 1Nuclear Medicine Division, Policlinico S Orsola, University of Bologna, Bologna, Italy.

The Lancet. Oncology
|December 4, 2018
PubMed
Summary

Developing guidelines for advanced prostate cancer imaging and radiopharmaceutical treatments is challenging. Experts recommend advanced imaging like MRI and PET-CT, but their clinical impact needs further study.